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Adiponectin: good, bad,  
or just plain ugly?
Tina Costacou1 and Trevor J. Orchard1
It has been suggested that adiponectin has antiatherogenic, anti-
inflammatory, and insulin-sensitizing properties. However, studies in 
humans have reported inverse as well as positive associations between 
adiponectin concentrations and disease states. This Commentary 
discusses the apparent conflict in the literature.
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Since the discovery of adiponectin, much 
has been said and even more has been 
hypothesized concerning its role in main-
taining health and responding to disease. 
However, the biologic activities of this adi-
pokine are still not well understood. It is 
known that adiponectin is a 30-kilodalton 
polypeptide belonging to the collectin fam-
ily and is specifically expressed in differ-
entiated adipocytes. It is present in trimer, 
hexamer, and high-molecular weight 
forms, whereas a proteolytic cleavage prod-
uct (known as globular adiponectin) has 
also been recognized. Although adiponec-
tin isoforms share common effects, they 
also induce isoform-specific responses, and 
it has been suggested that high-molecular 
weight adiponectin confers the vascular-
protective activities of this adipokine.1
As reviewed recently, antiatherogenic, 
anti-inflammatory, and insulin-sensitiz-
ing properties have been proposed for this 
molecule.1 Importantly, studies in human 
subjects have demonstrated that lower 
adiponectin concentrations are associated 
with obesity, severity of insulin resistance, 
and glucose intolerance,1 as well as cardio-
vascular disease among individuals with 
diabetes, both type 12 and type 2.3 Thus, 
the observations of markedly elevated con-
centrations of adiponectin among persons 
with type 1 diabetes,4 a state characterized 
by low-grade inflammation and increased 
cardiovascular risk, compared with per-
sons with normal glucose tolerance, were 
somewhat surprising and confusing. 
Equally surprising were the first cross-
sectional findings of increased adiponec-
tin levels in macroalbuminuria compared 
with states of normal albumin excretion or 
even microalbuminuria,5 as renal disease 
is considered a major risk factor for car-
diovascular disease in type 1 diabetes. The 
observed protective effect of this adipokine 
for cardiovascular outcomes is thus puz-
zling, as the same factor appears to render 
protection against one important outcome, 
cardiovascular disease, but is positively 
associated with another important out-
come, renal disease.
Nevertheless, a number of potential 
explanations have been suggested. Failure 
to establish temporal sequence has often 
been cited as a justification for the observed 
cross-sectional adiponectin elevations in 
macroalbuminuria in these early reports, 
as levels could potentially increase to coun-
teract harm caused by the disease process. 
Selective survival is another drawback of 
cross-sectional designs. However, results of 
the Mild to Moderate Kidney Disease Study 
demonstrating that adiponectin was an 
independent positive predictor of chronic 
kidney disease progression (defined as 
a doubling of the baseline serum creati-
nine and/or terminal renal failure) in 177 
patients who completed a 7-year follow-
up6 were also met with confusion, partly 
because the observed association was 
restricted to men. Now, the observational 
study by Jorsal et al.7 (this issue) provides 
further prospective evidence that elevated 
adiponectin levels may indeed predict 
mortality and progression to end-stage 
renal disease (ESRD) among those with a 
diagnosis of overt nephropathy in type 1 
diabetes. Interestingly, none of the eight 
common polymorphisms of the ADIPOQ 
gene studied was associated with any of the 
outcomes, which suggests either the lack 
of power to detect an association, or that 
there is indeed no adiponectin-associated 
genetic predisposition to renal disease 
progression.
Moreover, although the kidneys possibly 
play an important role in the biodegrada-
tion and/or elimination of adiponectin, 
recent evidence leads us to believe that 
altered clearance rates in renal damage are 
not likely to account for all of the observed 
increase in adiponectin concentrations in 
macroalbuminuria. Thus, Chudek et al.8 
showed that, despite having decreased 
from pretreatment levels, adiponectin 
concentration following transplantation 
was still twofold higher than the concen-
tration noted among healthy control indi-
viduals (15.7 versus 8.7 µg/ml, P < 0.01). 
These results possibly suggest that factors 
other than renal function influence the 
regulation of this protein in renal disease, 
a view further supported by findings of 
markedly increased adiponectin urinary 
excretion in individuals with type 2 diabe-
tes and overt nephropathy.9 It has further 
been argued that total adiponectin may not 
be the relevant factor and that its isoforms 
(especially the high-molecular weight 
form) should rather be assessed. However, 
Shen et al.10 recently showed that both total 
and high-molecular weight adiponectin 
were elevated in ESRD. Moreover, as in 
the study by Chudek et al.,8 Shen et al.10 
also demonstrated lower levels of total and 
high-molecular weight adiponectin among 
those having received a transplant com-
pared with persons with ESRD, although 
concentrations were still higher than in 
the control group. Interestingly, the pro-
portion of high-molecular weight to total 
adiponectin was similar between trans-
plant patients and controls, and lower in 
these latter groups (transplant patients and 
controls) than in patients with ESRD.
Consequently, the recent hypothesis that 
an elevation in adiponectin concentration 
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may occur in response to the microvascular 
damage seen in nephropathy (and other 
states) certainly appears more attractive, 
as it could potentially explain the observed 
inconsistencies. Should this hypothesis 
hold true, the absolute levels of either total 
or high-molecular weight adiponectin will 
prove to be difficult to interpret. A similar 
situation also exists with regard to another 
perceived protective factor, high-density 
lipoprotein cholesterol. Thus, it is possi-
ble that whereas low levels of adiponectin 
and high-density lipoprotein are gener-
ally reflective of decreased protection and 
predictive of increased events, a high level 
may be reflective of either adequate protec-
tion or response to a severe insult, which 
may in fact be adequate to protect. In all 
probability, it is in many cases a mixture 
of both. This is a plausible explanation for 
the high concentrations seen in high-risk 
states of this protective factor, as well as the 
varied results in terms of event prediction 
ranging from strongly protective to neu-
tral and even strongly positively related to 
adverse outcomes, as reported by Jorsal et 
al.7 Indeed, upregulation of adiponectin 
isoforms and receptor mRNA was recently 
reported in ESRD.11
It seems likely, then, that the conflict 
in the literature may reflect our inability 
to paint the complete picture. Although 
it is widely accepted that organisms have 
learned to mount a defense against patho-
genic insults, typically in epidemiology we 
tend to ignore this knowledge and study fac-
tors associated with disease risk separately 
from their counterpart factors representing 
protection or resistance to specific insults. 
Unfortunately, such assessments may not 
always accurately represent the processes 
leading to disease development, and thus 
it appears critical to simultaneously evalu-
ate not only the risk factor exposure but 
also the body’s (host) reaction. To provide 
an example of how dramatically differ-
ent conclusions can be drawn depending 
on the analytic strategy one follows, we 
present here previously unpublished data 
from a small subsample (n = 108) of par-
ticipants in the Epidemiology of Diabetes 
Complications Study of type 1 diabetes 
who had a diagnosis of overt nephropathy 
at study entry. During the 16-year follow-
up period, we observed elevations in the 
concentration of the inflammatory marker 
tumor necrosis factor-α with worsening 
of renal function, as estimated by 24-hour 
creatinine clearance, starting with an esti-
mated glomerular filtration rate (eGFR) less 
than 90 ml/min/1.73 m2. Similarly, higher 
adiponectin concentrations (both total and 
high-molecular weight adiponectin) were 
observed with declining eGFR.  Despite the 
latter elevations in adiponectin, however, 
the ratio of adiponectin to tumor necro-
sis factor-α (used as a potential marker 
of response to the increased stress from 
inflammation) decreased with declining 
eGFR (Figure 1). These data appear to 
provide support for the hypothesis that an 
individual’s risk of disease may depend on 
the individual’s ability to counteract stress 
produced by increased inflammation, and 
when that response is inadequate relative to 
the stress, disease progression occurs.  
Despite the above cross-sectional and 
thus speculative data, it is clear that the 
concurrent evaluation of markers repre-
senting, on one hand, insult, and on the 
other, response to insult, is going to be 
complex, for a number of reasons. It may 
not always be known whether a factor 
represents protection or harm for a given 
outcome, or even which protective factor is 
upregulated as a response to which insult. 
There are literally scores of potential ‘stres-
sors’ and ‘response/defense’ factors. More-
over, such strategies may entail the ability 
to recognize early changes in biomarker 
interrelationships, and difficulties often 
exist in establishing when disease initiation 
occurs, let alone identifying specifically 
related biomarkers of such early disease 
stages. Additionally, establishing a defini-
tion or characterization of an adequate 
response to a potential insult may also be 
challenging, as will consensus on the best 
statistical methodology to be applied in 
analyzing such data. Experimental and 
basic research may be better equipped 
to more easily address some of the issues 
raised, although it will take prospective 
investigations in human populations to 
reach a full understanding of these com-
plex interactions.
In conclusion, Odyssey or not, this 
exploratory  trip appears to be worth the 
effort, as the concurrent evaluation of insult 
and response to insult may lead to novel 
approaches to identifying both at-risk indi-
viduals and also pathways to preventing the 
progression of insults to full of disease.
DISCLOSURE 
The authors declared no competing interests.
REfEREnCES
1. Giannessi D, Maltinti M, Del Ry S. Adiponectin 
circulating levels: a new emerging biomarker 
of cardiovascular risk. Pharmacol Res 2007; 56: 
459–467.
2. Costacou T, Zgibor JC, Evans RW et al. The 
prospective association between adiponectin and 
coronary artery disease among individuals with 
type 1 diabetes. The Pittsburgh Epidemiology of 
Diabetes Complications Study. Diabetologia 2005; 
48: 41–48.
3. Hotta K, Funahashi T, Arita Y et al. Plasma 
concentrations of a novel, adipose-specific protein, 
adiponectin, in type 2 diabetic patients. Arterioscler 
Thromb Vasc Biol 2000; 20: 1595–1599.
4. Imagawa A, Funahashi T, Nakamura T et al. Elevated 
serum concentration of adipose-derived factor, 
adiponectin, in patients with type 1 diabetes. 
Diabetes Care 2002; 25: 1665–1666.
5. Saraheimo M, Forsblom C, Fagerudd J et al. 
Serum adiponectin is increased in type 1 diabetic 
patients with nephropathy. Diabetes Care 2005; 28: 
1410–1414.
6. Kollerits B, Fliser D, Heid IM et al. Gender-specific 
association of adiponectin as a predictor of 
progression of chronic kidney disease: the Mild to 
Moderate Kidney Disease Study. Kidney Int 2007; 71: 
1279–1286.
7. Jorsal A, Tarnow L, Frystyk J et al. Serum adiponectin 
predicts all-cause mortality and end stage renal 
figure 1 | Adiponectin, tumor necrosis factor-α (Tnf-α), and adiponectin-to-Tnf-α ratio by 
estimated glomerular filtration rate (eGfR).
TN
F-
α 
(pg
/m
l)
Ad
ip
on
ec
tin
 (µ
g/m
l)
16
14
12
10
8
6
4
2
0
5
4
3
2
1
0
>90
eGFR (ml/min/1.73 m2)
61–90 31–60 ≤30
Adiponectin Ratio TNF–α
Kidney International (2008) 74          551
commentar y
disease in patients with type I diabetes and diabetic 
nephropathy. Kidney Int 2008; 74: 649–654.  
8. Chudek J, Adamczak M, Karkoszka H et al. Plasma 
adiponectin concentration before and after 
successful kidney transplantation. Transplant Proc 
2003; 35: 2186–2189.
9. Koshimura J, Fujita H, Narita T et al. Urinary 
adiponectin excretion is increased in patients with 
overt diabetic nephropathy. Biochem Biophys Res 
Commun 2004; 316: 165–169.
10. Shen YY, Charlesworth JA, Kelly JJ et al. The effect 
of renal transplantation on adiponectin and its 
isoforms and receptors. Metabolism 2007; 56: 
1201–1208.
11. Shen YY, Charlesworth JA, Kelly JJ et al. 
Up-regulation of adiponectin, its isoforms and 
receptors in end-stage kidney disease. Nephrol Dial 
Transplant 2007; 22: 171–178.
see original article on page 585
Blocking of angiotensin II  
is more than blocking of 
transforming growth factor-β
Christoph Daniel1
Fibrosis is a common feature of chronic kidney diseases that is 
mediated by matrix-producing myofibroblasts. One potential origin 
of myofibroblasts is epithelial–mesenchymal transition (EMT) of 
tubuloepithelial cells. Transforming growth factor-β (TGF-β) is a key 
factor inducing EMT. Carvajal et al. demonstrate that angiotensin II 
induces EMT by classical stimulation of TGF-β and also by a TGF-β- 
independent pathway, both signaling via Smad molecules. Therefore, 
blockade of angiotensin II is more than lowering of blood pressure and 
inhibition of TGF-β stimulation.
Kidney International (2008) 74, 551–553. doi:10.1038/ki.2008.290
Chronic kidney diseases are emerging 
as a worldwide public-health problem. 
Recent reports suggest that up to 10% of 
the population may be affected by chronic 
kidney disease (CKD).1 Irrespective of the 
underlying cause, CKD is linked with the 
development of glomerulosclerosis and 
tubulointerstitial fibrosis, which is the 
major cause of end-stage renal disease in 
humans. Fibrosis is characterized by accu-
mulation of matrix molecules such as colla-
gens and fibronectin due to overexpression 
and decreased clearing and degradation of 
these matrix components. The key cellular 
mediator of fibrosis is the myofibroblast, 
which, when activated, serves as the pri-
mary collagen-producing cell.2 In addition 
to activated local tissue fibroblasts, myofi-
broblasts can originate from circulating 
mesenchymal progenitors or from epithe-
lial cells in a process known as epithelial–
mesenchymal transition (EMT).2 The 
process of EMT includes disaggregation 
of epithelial units and reshaping of epi-
thelia for movement. During transition, 
epithelial cells lose polarity, adherens 
junctions, tight junctions, desmosomes, 
and cytokeratin intermediate filaments in 
order to rearrange their F-actin stress fibers 
and express filopodia and lamellopodia.3 
Molecular markers of this transition proc-
ess are, for example, increased expression 
of vimentin and α-smooth muscle actin 
and loss of E-cadherin expression.3 Dif-
ferent cytokines and metalloproteinases 
have been identified as being involved in 
the induction of EMT. One key player for 
EMT induction is transforming growth 
factor-β (TGF-β). TGF-β promotes EMT 
by several mechanisms, but the Smad path-
way is the most relevant. Additionally, the 
renin–angiotensin–aldosterone system is 
a known modulator of renal fibrosis. It is 
well accepted that angiotensin II (Ang II) 
induces TGF-β, but less is known about 
potential TGF–β-independent actions of 
Ang II on fibrosis and EMT. The article by 
Carvajal and co-workers4 (this issue) elu-
cidates an additional role of Ang II in the 
induction of EMT besides its effects medi-
ated by TGF-β.
This group showed that stimulatory 
effects of Ang II-induced EMT can be 
divided in two phases, an early, acute 
TGF-β–independent and a late TGF-β–
dependent phase. Ang II phosphorylated 
tubuloepithelial Smad2 and Smad3 as early 
as 24 hours after infusion in rats. At this 
time point after Ang II infusion, neither 
TGF-β nor the potential TGF-β activator 
thrombospondin 1 was increased, sug-
gesting that Smad2/3 phosphorylation is 
TGF-β independent (Figure 1). In Ang II 
stimulation experiments using cultured 
human tubuloepithelial cells, the authors 
confirmed that Ang II rapidly activates the 
Smad pathway by a TGF-β–independent 
mechanism using TGF-β–neutralizing 
antibody or a TGF-β receptor blocker. Spe-
cific blockade of p38–mitogen-activated 
protein kinase (p38-MAPK), extracellu-
lar signal-regulated kinase-1/2 (ERK1/2), 
and Jun kinase during Ang II stimulation 
revealed that all three kinases are involved 
in early activation of the Smad pathway.
This mechanism of TGF-β–independent 
Smad2 and Smad3 activation by Ang II 
is not restricted to the kidney. Recent 
studies using vascular smooth muscle 
cells (VSMCs) also demonstrated TGF-
β–independent Smad activation mediated 
by MAPK,5,6 suggesting that this pathway 
is used in cells of different organs. Interest-
ingly, Smad phosphorylation in VSMCs was 
mediated by p385 or ERK1/2.6 Although 
both Smad2 and Smad3 were activated by 
Ang II by a TGF-β–independent mecha-
nism, only phosphorylation of Smad3 was 
found to be important for upregulation of 
collagen I in VSMCs, as was demonstrated 
by the use of VSMCs defective in either 
Smad2 or Smad3.6 For tubuloepithelial cells 
it is not known whether Smad2, Smad3, 
or both are required for the induction 
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